List
The results of your search are listed below. To view the details of a trial or study, click on the "SEE DETAILS" button. Or start a new search.
Searched for: Head and Neck Cancer. 16 results shown below.
Durvalumab, Tremelimumab and Stereotactic Body Radiation Therapy in Treating Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Complete title: Durvalumab (MEDI4736), Tremelimumab and Palliative Hypofractionated Image Guided Radiation Therapy (HIGRT) in Patients with Recurrent/Metastatic Squamous Cell Carcinomas of the Head and Neck Previously Treated with Immune Checkpoint Inhibitors
Principal Investigator: Cristina Rodriguez
Study Number: 9881
Phase: I/II
Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers
Complete title: Dual Immune Checkpoint Blockade and Hypofractionated Radiation in Patients with Salivary Gland Cancers
Principal Investigator: Cristina Rodriguez
Study Number: RG1718030
Phase: I/II
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
Complete title: Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Principal Investigator: Smith Apisarnthanarax
Study Number: RG1006867
Phase: III
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
Complete title: A Randomized Phase II / Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Principal Investigator: Cristina Rodriguez
Study Number: RTOG-1008
Phase: II/III
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Complete title: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Principal Investigator: Heidi Gray, MD
Study Number: S1609
Phase: II
Safety Study of SEA-CD40 in Cancer Patients
Complete title: A Phase 1, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies
Principal Investigator: Andrew Coveler, MD
Study Number: 20150420
Phase: I
A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors
Complete title: A Phase 1 Study of SL-801, a Reversible Inhibitor of Nuclear Export, in Patients with Advanced Solid Tumors
Principal Investigator: Gabriela Chiorean
Study Number: 20160524
Phase: I
A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Complete title: A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS
Principal Investigator: Kit Wong
Study Number: 20171486
Phase: I
Phase 1 Study of the Highly-selective RET Inhibitor BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
Complete title: A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-small Cell Lung Cancer (NSCLC) and other Advanced Solid Tumors
Principal Investigator: Christina Baik
Study Number: 20172740
Phase: I/II
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
Complete title: A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
Principal Investigator: Cristina Rodriguez
Study Number: 20173067
Phase: III
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
Complete title: A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus
Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE 811)
Principal Investigator: Veena Shankaran
Study Number: RG1003347
Phase: III
A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC
Complete title: A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Platin-Resistant Oropharyngeal Cancer (OPC)
Principal Investigator: Rafael Santana-Davila
Study Number: RG1003431
Phase: II
Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (AIM-HN/SEQ-HN)
Complete title: The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)
Principal Investigator: Cristina Rodriguez
Study Number: RG1003666
Phase: II
A Phase 1 Study in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
Complete title: A PHASE 1, FIRST-IN-HUMAN, OPEN-LABEL, DOSE
ESCALATION AND EXPANSION STUDY OF CUE-101
MONOTHERAPY IN PATIENTS WITH HPV+
RECURRENT/ METASTATIC HEAD AND NECK
SQUAMOUS CELL CARCINOMA (HNSCC)
Principal Investigator: Cristina Rodriguez
Study Number: RG1005866
Phase: I
Intratumoral Microdosing of TAK-981 in Head and Neck Cancer
Complete title: Evaluation of TAK-981 and TAK-981 Combinations Following Intratumoral CIVO� Microdosing in Patients with Head and Neck Cancer
Principal Investigator: Jeffrey Houlton
Study Number: RG1006979
Phase: Early Phase I
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Complete title: Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies
Principal Investigator: Gabriela Chiorean
Study Number: RG1121312
Phase: N/A